CoChat

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

Open access
Gauci, Marie-Léa, Aristei, Cynthia, Becker, Jurgen C., Blom, Astrid, Bataille, Veronique, Dreno, Brigitte, Del Marmol, Veronique, Forsea, Ana M., Fargnoli, Maria C., Grob, Jean-Jacques, Gomes, Fabio, Hauschild, Axel, Hoeller, Christoph, Harwood, Catherine, Kelleners-Smeets, Nicole, Kaufmann, Roland, Lallas, Aimilios, Malvehy, Josep, Moreno-Ramirez, David, Peris, Ketty, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J., Vieira, Ricardo, Zalaudek, Iris, van Akkooi, Alexander C.J., Lorigan, Paul, Garbe, Claus, Lebbé, Céleste · 2022 · European Journal of Cancer
Cited by 192

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all cutaneous malignancies. It is found predominantly in white populations and risk factors include advanced age, ultraviolet exposure, male sex, immunosuppression, such as AIDS/HIV infection, haematological malignancies or solid organ transplantation, and Merkel cell polyomavirus infection. MCC is an aggressive tumour with 26% of cases presenting lymph node involvement at diagnosis and 8% with distant metastases. Five-year overall survival rates range between 48% and 63%. Two subsets of MCC have been characterised with distinct molecular pathogenetic pathways: ultraviolet-induced MCC versus virus-positive MCC, which carries a better prognosis. In both subtypes, there are alterations in the retinoblastoma protein and p53 gene structure and function. MCC typically manifests as a red nodule or plaque with fast growth, most commonly on sun exposed areas. Histopathology (small-cell neuroendocrine appearance) and immunohistochemistry (CK20 positivity and TTF-1 negativity) confirm the diagnosis. The current staging systems are the American Joint Committee on Cancer/Union for international Cancer control 8th edition. Baseline whole body imaging is encouraged to rule out regional and distant metastasis. For localised MCC, first-line treatment is surgical excision with postoperative margin assessment followed by adjuvant radiation therapy (RT). Sentinel lymph node biopsy is recommended in all patients with MCC without clinically detectable lymph nodes or distant metastasis. Adjuvant RT alone, eventually combined with complete lymph nodes dissection is proposed in case of micrometastatic nodal involvement. In case of macroscopic nodal involvement, the standard of care is complete lymph nodes dissection potentially followed by post-operative RT. Immunotherapy with anti-PD-(L)1 antibodies should be offered as first-line systemic treatment in advanced MCC. Chemotherapy can be used when patients fail to respond or are intolerant for anti-PD-(L)1 immunotherapy or clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2022.03.043

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 192

Metadata

Authors
Gauci, M.-L., Aristei, C., Becker, J. C., Blom, A., Bataille, V., Dreno, B., Del Marmol, V., Forsea, A. M., Fargnoli, M. C., Grob, J.-J., Gomes, F., Hauschild, A., Hoeller, C., Harwood, C., Kelleners-Smeets, N., Kaufmann, R., Lallas, A., Malvehy, J., Moreno-Ramirez, D., Peris, K., Pellacani, G., Saiag, P., Stratigos, A. J., Vieira, R., Zalaudek, I., van Akkooi, A. C. J., Lorigan, P., Garbe, C., & Lebbé, C.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2022-08
Volume
171
Pages
203-231
ISSN
0959-8049 (ISSN-L)
OpenAlex
W4283118026
Cited by
192
References
10
FWCI
13.87
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022. https://app.cochat.ai/papers/10.1016/j.ejca.2022.03.043
The paper
Gauci, M.-L., Aristei, C., Becker, J. C., Blom, A., Bataille, V., Dreno, B., Del Marmol, V., Forsea, A. M., Fargnoli, M. C., Grob, J.-J., Gomes, F., Hauschild, A., Hoeller, C., Harwood, C., Kelleners-Smeets, N., Kaufmann, R., Lallas, A., Malvehy, J., Moreno-Ramirez, D., . . . Lebbé, C. (2022). Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2022.03.043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.